Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery

By L. E. V. Vlerken, Tushar K. Vyas, M. Amiji. Pharmaceutical Research, 2007

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nanoparticle PEGylation for imaging and therapy (2011, background): “NPs aggregate primarily because the attraction between particles is stronger than the attraction for solvent [13,24].”
Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications (2016, unknown): “[106 ,107] Long circulation of carriers would prevent active targeting and cellular uptake.”
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “Furthermore, surface modification of PLGA nanoparticles with PEG greatly increases the circulation time and retention of nanoparticles in tumor sites In vivo [124].”
Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles (2010, background): “PEG-modified nanoparticles are more stable at high salt concentrations and in biological environments; they show less non-specific binding to proteins and cells (Gref et al. 2000; Ballou et al. 2004; Liu et al. 2007b, 2008; van Vlerken et al. 2007; Daou et al. 2009).”